Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proteasome inhibition leads to accumulation of transcription factors, heat shock proteins, cyclins, and other proteasome substrate proteins by blocking their proteolytic degradation. An increase in gene transcription upon proteasome inhibition was found for a group of proteins, including p21(WAF1/CIP1), ubiquitin, and transcription factors. In this study, we have demonstrated selective up-regulation of
extracellular signal-regulated kinase 3
(
ERK3
) mRNA and protein expression upon treatment with peptide-based proteasome inhibitors or lactacystin.
ERK3
is a family member of the mitogen-activated protein kinases (also called ERK) that are key mediators of signal transduction from the cell surface to the nucleus.
ERK3
up-regulation is independent of the p53, Bcl2, and
caspase 3
status of cells. p38 pathway kinase inhibitors prevent proteasome-dependent
ERK3
induction and enhance the antiproliferative effect of proteasome inhibitors. MCF-7 cells expressing
ERK3
ectopically show increased resistance toward proteasome inhibition. The results indicate that
ERK3
expression is a consequence of p38 pathway activation and most probably represents an intracellular defense or rescue mechanism against cell stress and damage induced by proteasome inhibition.
...
PMID:Proteasome- and p38-dependent regulation of ERK3 expression. 1114 4